Jam

Sarepta Therapeutics is voluntarily pausing ELEVIDYS shipments in the U.S. to facilitate information exchange with the FDA and finalize safety labeling. This gene therapy treats Duchenne muscular dystrophy by delivering a micro-dystrophin gene. The pause will take effect July 22, 2025. The company emphasizes patient safety and maintaining a productive relationship with the FDA. ELEVIDYS is approved for Duchenne patients aged 4+ with confirmed DMD gene mutations.

Asbury Automotive Group closed its acquisition of The Herb Chambers Companies (HCC), the 16th largest privately-owned dealership group nationwide, marking Asbury’s entry into the Northeastern US market. The $1.45 billion deal includes 33 dealerships representing 52 franchises and is expected to generate significant shareholder value. HCC moved approximately 50,000 vehicles in 2024 and is known for its customer service. Asbury financed the acquisition through credit and cash.

Financial advisors Chuck Heare, Ross Heare, Tommy Goth, and Jennifer Goth-Castillo, managing $480 million in client assets, have joined Q5 Wealth Management, an existing Ameriprise practice, from UBS Financial Services. Motivations included Ameriprise’s client-first culture, the freedom to build out support models, and shared values. Q5 has experienced significant growth, adding Scott Guptill and Kurtis Bell, and now manages over $1.9 billion in client assets with a team of 11 advisors and 7 support staff.

CenterPoint Energy has appointed Jesus Soto, Jr. as its new Executive Vice President and Chief Operating Officer, effective August 11, 2025. Soto, with over 30 years of energy sector experience, will oversee Electric Operations, Gas Operations, Safety, Supply Chain, and Customer Care, reporting directly to the CEO. He is known for operational excellence, successful capital project execution, and fostering safety cultures. This appointment supports CenterPoint’s planned $31 billion capital investment, enhancing safety and reliability for customers across Texas, Indiana, Ohio, and Minnesota.

Goodyear is donating its last-remaining GZ20 blimp gondola to the EAA Museum for a children’s exhibit as part of its blimp program’s centennial. The gondola, which served on the *Europa* and *Stars and Stripes* blimps, will inspire future aviation enthusiasts. Goodyear is also offering a limited-edition collectible featuring a piece of the *Spirit of Goodyear* blimp, with proceeds benefiting the EAA Museum. Goodyear is showcasing its aviation tires and blimps at EAA AirVenture Oshkosh 2025.

This article snippet likely pertains to news or article content, indicated by elements like “news-card-body” and “news-card-summary”. It seems to involve a client-side “parseRating” function and related tools (article-rhea-tools). The structure suggests it displays summaries or excerpts of news articles, potentially with ratings or other interactive elements.

CoreWeave (Nasdaq: CRWV) announced a private offering of $1.5 billion in senior notes due 2031, guaranteed by its subsidiaries. The AI hyperscaler intends to use the proceeds to repay debt and cover expenses, bolstering its position in the expanding AI infrastructure market. The offering targets qualified institutional buyers and non-U.S. persons, adhering to securities regulations. CoreWeave provides cloud solutions for accelerated computing and cautions investors about forward-looking statements, advising due diligence and consulting SEC filings.

Blackrock Silver has commenced a fully-funded 5,000-meter expansion drill program at its Tonopah West project in Nevada. Following successful scout drilling, which extended the DPB South zone 1,200 meters eastward, the program will utilize three drill rigs across 15 holes. Scout drilling revealed high-grade mineralization, including 2,063 g/t silver equivalent over 1.52 meters. This newly defined zone, outside the 2024 resource, offers significant growth potential. Program completion is expected in October, with results incorporated into a Q1 2026 resource update.

Stellantis reported preliminary unaudited H1 2025 results showing €74.3B net revenues but a €2.3B net loss and -€3.0B industrial free cash flow. Q2 global shipments declined 6% to 1.4M units. Results were impacted by €3.3B in charges for program cancellations, platform impairments, and restructuring, plus €0.3B from US tariffs. North American shipments fell 25%. Positive growth was seen in Middle East & Africa (30%) and South America (20%). The company anticipates improvement in H2 2025.

Genentech announced topline results from the Phase IIb ALIENTO and Phase III ARNASA trials evaluating astegolimab for COPD. ALIENTO met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks. However, ARNASA did not meet its primary endpoint, despite a numerical reduction in AER. Astegolimab’s safety profile remained consistent with prior data. Genentech will discuss the data with regulatory authorities and present it at a future medical meeting. The trials included diverse COPD patients.